Growth Response in Girls With Turner Syndrome

Novo Nordisk A/S31 enrolled

Overview

This trial is conducted in Europe. The aim of the trial is to evaluate growth response of two somatropin dose regimens in girls with Turner Syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Genetic Disorder Turner Syndrome

Interventions

somatropinDRUG

0.9 UI/kg/week. Subcutaneous injection for 3 years

somatropinDRUG

1.8 UI/kg/week. Subcutaneous injection for 3 years

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Turner syndrome * If age below 3 years, either body height below - 1 SD (standard deviation) with average growth velocity according to chronological age or body height below 0 SD with growth velocity below -1 SD according to chronological age * If age above 3 years, body height below - 1 SD with average growth velocity according to chronological age * Measured parental height available * Written informed consent

Locations (15)

Novo Nordisk Investigational Site

Besançon, France

Novo Nordisk Investigational Site

Bordeaux, France

Novo Nordisk Investigational Site

Dunkirk, France

Outcomes

Primary Outcomes

Height gain, SDS (Standard Deviation Score)

Height gain in cm

Secondary Outcomes

Height

Bone maturation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.